Control Bionics Eyes Four Global Markets With Deals, Insurance Wins and Apple BCI Push

By Josua Ferreira -

Control Bionics builds global commercial momentum across three platforms

Control Bionics Limited (ASX: CBL) has reported concurrent progress across its three neurotechnology divisions, with distribution partnerships, reimbursement access, enterprise sports adoption, and next-generation software development all advancing. The 4 June 2026 commercial update covers the Assistive Technology, Neurotechnology Solutions, and Medical Technology pillars, reflecting the company’s strategy to expand its neural interface platform across multiple global markets.

Assistive Technology — distribution partnerships and reimbursement milestones

CBL’s Assistive Technology division has secured a series of commercial and market access milestones over the past six months. The foundation was the allocation of the E2513 HCPCS billing code in the US, which enabled the company to execute nationwide distribution agreements with both Tobii Dynavox and PRC-Saltillo in January 2026.

In Europe, CBL secured HMV insurance coverage in Germany in February 2026, establishing a funded market entry pathway for the NextLevel device in a major European territory. Product expansion continued with an April 2026 letter of intent for 1,000 NextLevel iOS-based communication devices, featuring a US$100,000 upfront component and a partner-led distribution model.

CBL has also established an insurance billing model in the US through Mountain Land Physical Therapy, creating a reimbursed service pathway that extends beyond device sales alone.

Assistive Technology milestones at a glance:

  • January 2026: US distribution agreements executed with Tobii Dynavox and PRC-Saltillo, following E2513 HCPCS billing code allocation
  • February 2026: HMV insurance coverage secured in Germany, establishing a funded European market entry
  • April 2026: Letter of intent signed for 1,000 NextLevel iOS-based communication devices, with US$100,000 upfront payment

What the E2513 billing code means for investors

An HCPCS (Healthcare Common Procedure Coding System) billing code is a standardised identifier used by healthcare providers in the US to submit claims for reimbursement to Medicare, Medicaid, and private insurers. Securing the E2513 code means CBL’s device can now be billed through the US insurance system, which is often the single largest barrier to adoption for medical device companies. Without a billing code, clinicians may avoid prescribing a product simply because patients cannot get it covered. With one in place, the commercial pathway broadens considerably.

NeuroStrip gains elite sports and clinical validation

CBL’s NeuroTechnology Solutions division is advancing structured evaluation programs for its wearable sEMG platform, NeuroStrip, across both elite sports organisations and clinical institutions. Programs are currently underway with AFL clubs, NRL clubs, the Australian Institute of Sport, Ohio University, and others.

The three primary use cases being validated across these programs are athlete monitoring, rehabilitation, and return-to-play decision-making. It is important to note that these remain structured evaluation programs; the source does not characterise the participating sports organisations as paying commercial customers at this stage.

Clinical evidence for the platform’s therapeutic applications has also emerged from Japan, where a Stroke Lab study reported a 39% reduction in muscle overactivity using NeuroStrip application. This outcome is specific to that study and should not be generalised across all applications.

Organisation Sector Application Geography
AFL Clubs Elite Sport Athlete monitoring, return-to-play Australia
NRL Clubs Elite Sport Athlete monitoring, rehabilitation Australia
Australian Institute of Sport Elite Sport / Government Athlete monitoring, performance Australia
Ohio University Academic / Clinical Rehabilitation, research North America
Mountain Land Physical Therapy Clinical / Rehabilitation Insurance-reimbursed service model North America
Stroke Lab Japan Clinical Research Muscle overactivity reduction study Japan

Apple BCI integration — what’s coming in Q3 2026

CBL is developing Apple BCI (Brain-Computer Interface) protocol integration as a next-generation software capability for the NeuroStrip platform. A global commercial release is targeted for Q3 2026. This integration remains in development and represents a forward-looking milestone; if delivered, it could meaningfully expand the platform’s addressable market by connecting NeuroStrip to Apple’s accessibility ecosystem.

Building a diversified global commercial platform

Taken together, the milestones disclosed across CBL’s three divisions point to a company building commercial infrastructure in four geographies simultaneously: North America, Australia, Europe, and Japan. A dual-revenue model appears to be taking shape, with device sales through distribution partners alongside insurance-reimbursed service arrangements.

CEO and Managing Director Jeremy Steele

“The commercial progress across our platforms reflects the scalability of our neural interface technology beyond assistive communication. With established distribution partnerships, new reimbursed markets, and growing enterprise adoption, we are building a diversified global commercial platform.”

Looking ahead, the targeted Q3 2026 Apple BCI integration release and the continued expansion of NeuroStrip evaluation programs represent the near-term catalysts investors will be monitoring as CBL works to convert commercial validation into sustained revenue across its platform.

Don’t Miss the Next Healthcare Breakout

Big News Blast delivers FREE breaking ASX healthcare and biotech news to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who stay ahead of the market the moment announcements hit. Click the “Free Alerts” button to start receiving real-time coverage today.


Frequently Asked Questions

What is the E2513 HCPCS billing code and why does it matter for Control Bionics?

The E2513 HCPCS billing code is a standardised US identifier that allows healthcare providers to submit insurance claims for CBL's devices to Medicare, Medicaid, and private insurers — removing the reimbursement barrier that often prevents clinicians from prescribing medical devices and enabling CBL to execute nationwide distribution agreements with Tobii Dynavox and PRC-Saltillo.

What is NeuroStrip and how is Control Bionics commercialising it?

NeuroStrip is Control Bionics' wearable surface electromyography (sEMG) platform being evaluated across elite sports organisations including AFL and NRL clubs, the Australian Institute of Sport, and clinical institutions such as Ohio University, with use cases spanning athlete monitoring, rehabilitation, and return-to-play decision-making.

When is Control Bionics planning to release its Apple BCI integration for NeuroStrip?

CBL is targeting a global commercial release of the Apple Brain-Computer Interface protocol integration for the NeuroStrip platform in Q3 2026, though this milestone remains in development and is not yet confirmed as complete.

What clinical evidence exists for NeuroStrip's therapeutic applications?

A Stroke Lab study conducted in Japan reported a 39% reduction in muscle overactivity using NeuroStrip application; however, CBL cautions this outcome is specific to that single study and should not be generalised across all platform applications.

Which markets is Control Bionics targeting for commercial expansion in 2026?

Control Bionics is simultaneously building commercial infrastructure across four geographies — North America, Australia, Europe, and Japan — through a combination of distribution partnerships, insurance reimbursement agreements, and structured enterprise evaluation programs.

Josua Ferreira
By Josua Ferreira
Partnership Director
Josua Ferreira holds a Bachelor of Commerce in Marketing and Advertising and brings a background in publication, business development, and ASX market storytelling. He has worked with listed companies across the resource sector and broader market, combining sharp commercial instincts with a genuine commitment to keeping investors informed.
Learn More
Companies Mentioned in Article

Breaking ASX Alerts Direct to Your Inbox

Join +20,000 subscribers receiving alerts.

Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.

About the Publisher